Live Market Updates: Sensex, Nifty rally, BHEL up 3%; FM arriv...

TCS, Hero, Cipla, Maruti and Infosys are down while Tata Steel, HDFC, LT, ICICI Bank and BHEL are among the gainers in the Sensex.

Cipla Limited, a pharmaceutical company, has reported that net profit after tax for the third quarter ended December 31, 2014 was INR3.34 billion, or INR4.07 per diluted share, compared to INR2.96 billion, or INR3.54 per diluted share, for the same ...

The National Pharmaceutical Pricing Authority (NPPA) has directed the drug manufacturers Cipla, Hetero, Ranbaxy and Strides Acrolabs to ensure smooth supply of medicines following the rising number of deaths due to swine flu as also to meet soaring ...

MUMBAI: Stocks of Cipla advanced over 2 per cent on Thursday on reports that the pharma major is looking to increase its presence in the American market by acquiring US-based companies. Sources indicated that Cipla is in talks to acquire companies ...

Othe rplayers are also in fray includes Intas pharma and Emcure.

Centrum Broking CMP: ₹670.40 Target: ₹790 Cipla has reported 14 per cent y-o-y growth in domestic revenues (43 per cent of total) to ₹1,200 crore from ₹1,050 crore due to strong growth in respiratory, anti-infective, cardiovascular and ...

Cipla has been selected by the Global Fund to produce anti-retroviral drugs for the next three years. Asian Scientist Newsroom | February 23, 2015 | Pharma AsianScientist (Feb. 23, 2015) - Cipla Ltd., an Indian pharmaceutical company, has ...

Indian firm Cipla's UK subsidiary has entered into a joint venture to establish a stronger presence in Morocco, as it sets its sights on expansion into the Middle East and North African markets. The agreement, in which Cipla is investing $15 ...

Mumbai : Pharmaceutical major Cipla plans to name its hepatitis C drug with Gilead Sciences as Hepcvir, its chairman Yusuf K Hamied on Wednesday. Last year Gilead Sciences has licensed its hepatitis C drug Sovaldi (chemically known as sofosbufir) to ...